Printer Friendly

PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT

 PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM
 ANNOUNCE VACCINE AGREEMENT
 PHILADELPHIA, June 16 /PRNewswire/ -- Pasteur Merieux Serums et Vaccins with Connaught Laboratories, Inc. and SmithKline Beecham (NYSE: SBH) (SB) today announced an agreement in principle under which SmithKline Beecham would obtain rights to manufacture and sell in the U.S. Pasteur Merieux's Haemophilus influenzae type b (PRP-T) vaccine in single dosage form and in combination with other pediatric vaccines.
 The vaccine is currently awaiting FDA approval.
 Under the agreement, Pasteur Merieux will supply SmithKline Beecham with the Haemophilus influenzae type b (PRP-T) vaccine for U.S. marketing until SmithKline Beecham manufactures the vaccine itself.
 SmithKline Beecham said the agreement would facilitate its participation in the U.S. market for pediatric vaccines -- to protect the very young from such diseases as Haemophilus influenzae type b, diphtheria, tetanus, pertussis, polio and hepatitis B. Pasteur Merieux will continue to make PRP-T vaccine available in other countries outside the United States.
 Pasteur-Merieux-Connaught said that such an agreement between major biological companies will contribute to improve vaccinal cover, especially for children.
 SmithKline Beecham presently markets a variety of vaccines around the world, including vaccines against polio, hepatitis B, measles, mumps, rubella and meningitis. The company is the world's largest supplier of polio vaccine and has recently launched, in Switzerland, Belgium and the United Kingdom, Havrix, the world's first hepatitis A vaccine.
 Pasteur Merieux Serums et Vaccins and Connaught Laboratories are part of Institut Merieux, the world leader in human and animal biology.
 Connaught Laboratories, Inc. provides the broadest range of human vaccines and biologicals commercially available in the United States from a single company, supplying, among others, DTP, polio, influenza, Haemophilus influenzae type b (PRP-D), rabies, Meningococcal and yellow fever vaccines.
 Final agreement is subject to review by the boards of directors of both companies.
 /delval/
 -0- 6/16/92
 /CONTACT: Doug Reynolds of Connaught, 717-839-4235, or Jeremy Heymsfeld of SmithKline Beecham, 215-751-7709/
 (SBH) CO: Pasteur Merieux Serums et Vaccins; Connaught Laboratories, Inc.;
 SmithKline Beecham ST: Pennsylvania IN: MTC SU:


CC -- PH006 -- 0526 06/16/92 09:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:345
Previous Article:MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
Next Article:SOMATIX RECEIVES EXCLUSIVE WORLDWIDE LICENSE ON CANCER GENE THERAPY PATENT APPLICATION
Topics:


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
RIBI IMMUNOCHEM EXPANDS COMMERCIAL RELATIONSHIP WITH SMITHKLINE BEECHAM BY PROVIDING ADJUVANTS FOR IMPORTANT GROUP OF BACTERIAL VACCINES
SMITHKLINE BEECHAM ANNOUNCES PEDIATRIC VACCINE AGREEMENT WITH MEDEVA
PASTEUR MERIEUX-CONNAUGHT SIGNS A RESEARCH AGREEMENT WITH THE AGENCE NATIONALE DE RECHERCHES SUR LE SIDA
TULANE UNIVERSITY AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
MICROCARB RECEIVES MILESTONE PAYMENT
Pasteur Merieux Connaught and Cistron Biotechnology Enter Into a Letter of Intent for an Equity Investment and an Interleukin-1b Vaccine Adjuvant...
Corixa Announces Extension of Vaccine Adjuvant Research Agreement and Option Agreement with Pasteur Merieux Connaught (Rhone-Poulenc Group)
Antex Biologics Receives Defense Department Contract for Development Of A Combination Traveler's Vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters